Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Bicara Therapeutics Inc. ( (BCAX) ).
On May 21, 2026, Bicara Therapeutics reported three-year follow-up data from a Phase 1/1b study of ficerafusp alfa plus pembrolizumab in first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma, showing deep, durable responses and a generally well-tolerated safety profile across three dose cohorts. At the pivotal 1500mg weekly dose, the regimen delivered an estimated 31% overall survival at three years, roughly double a retrospective standard-of-care benchmark, with high complete and deep response rates, and pooled analyses indicated that greater TGF-β inhibition and ≥80% tumor shrinkage correlated with markedly improved duration of response, progression-free survival and overall survival, reinforcing the drug’s emerging best-in-class profile and informing Bicara’s ongoing Phase 3 FORTIFI-HN01 program and future dosing strategy.
The most recent analyst rating on (BCAX) stock is a Buy with a $46.00 price target. To see the full list of analyst forecasts on Bicara Therapeutics Inc. stock, see the BCAX Stock Forecast page.
Spark’s Take on BCAX Stock
According to Spark, TipRanks’ AI Analyst, BCAX is a Neutral.
The score is held back mainly by weak current financial performance (pre-revenue, widening losses, and heavy cash burn) and negative technical momentum. Offsetting these is a strong balance sheet and a constructive earnings update with clear clinical milestones and multi-year cash runway, but execution and trial/regulatory risks remain material.
To see Spark’s full report on BCAX stock, click here.
More about Bicara Therapeutics Inc.
Bicara Therapeutics Inc. is a Boston-based, clinical-stage biopharmaceutical company focused on developing transformative bifunctional therapies for patients with solid tumors. Its lead asset, ficerafusp alfa, is an EGFR-directed monoclonal antibody linked to a TGF-β ligand trap designed to improve tumor penetration, deepen responses and potentially extend survival in difficult-to-treat cancers such as HPV-negative head and neck squamous cell carcinoma.
Average Trading Volume: 582,107
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.34B
Find detailed analytics on BCAX stock on TipRanks’ Stock Analysis page.